MedTrace Logo

Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)

NCT01078415 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2016-11-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of the NanoKnife LEDC System for the treatment of early-stage hepatocellular carcinoma (HCC).

Conditions

  • Carcinoma, Hepatocellular

Interventions

DEVICE

Ablation with the NanoKnife Low Energy Direct Current (LEDC) System

90 pulses of 70 microseconds each in duration will be administered per electrode pair.

Sponsors & Collaborators

  • Angiodynamics, Inc.

    lead INDUSTRY

Principal Investigators

  • Riccardo Lencioni, MD · University of Pisa School of Medicine

  • Jordi Bruix, MD · Barcelona Clinic Liver Cancer (BCLC) Group of the University of Barcelona

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2013-01-31
Completion
2013-06-30

Countries

  • France
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01078415 on ClinicalTrials.gov